Endocrine Complications in Pediatric Beta-Thalassemia Major Patients: A Single-Center Experience

Authors : Fatma DEMİR YENİGURBUZ, Burcu AKINCI, Ala ÜSTYOL, Deniz ÖKDEMİR, Ahmet SEZER

Pages : 556-562

Doi:10.35440/hutfd.1144199

View : 16 | Download : 8

Publication Date : 2022-12-27

Article Type : Research Paper

Abstract :Background: We aimed to investigate the risk factors and clinical correlates of endocrine complications in β-thalassemia major insert ignore into journalissuearticles values(BTM); patients. Materials and methods: This retrospective study was performed in the pediatric hematology and pediatric endocrinology departments of a tertiary care center using data derived from medical records of 249 children with BTM insert ignore into journalissuearticles values(108 females, 43.4%; 141 males, 56.6%); with a median age of 7.17 insert ignore into journalissuearticles values(range: 2 to 17.83); years. Baseline descriptive, clinical features including endocrine complications and laboratory data were noted. Correlation between the presence of endocrine complications and demographic, clinical, and laboratory variables were sought. Results: The majority of BTM patients insert ignore into journalissuearticles values(n=169, 67.9%); had at least one endocrine complication. Syrian patients had lower levels of vitamin D and were more likely to have subclinical hypothyroidism. Patients with advanced age, delayed puberty, Syrian nationality, and short stature were more likely to suffer from at least one endocrine complication. Conclusion: Endocrine and metabolic disorders are very common in children with BTM. Early detection of these disorders, as well as multidisciplinary management with standardized protocols constitutes the most suitable strategy to provide a better quality of life for these patients. Regular surveillance, early diagnosis, treatment, and follow-up with the collaboration of a multidisciplinary team are the key points in the reduction of the severity and frequency of endocrine complications as well as optimization of therapeutic outcomes.
Keywords : beta thalassemia major, endocrine complication, treatment, Beta thalasemia major, endocrin, complications, treatment, endocrin, complications, treatment